2026 Q2 - tulosraportti
69 päivää sitten
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 27.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 28.8. | ||
2026 Q1 - tulosraportti 28.5. | ||
2025 Q4 - tulosraportti 11.2. | ||
2025 Q3 - tulosraportti 27.11.2025 | ||
2025 Q2 - tulosraportti 20.8.2025 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
·27.10. · MuokattuOj... was a shareholder in the company many years ago. I recall that when I went through all the share issues that the company had made over all the years on the stock exchange, these amounted to a total of around 200m (someone is welcome to check this). Possible if one changes the sales model around the instruments, that this could be the solution to the problem. A change from direct sales (CAPEX decision) to operational leasing (OPEX decision) definitely changes/shortens the sales process as the hospitals do not need CAPEX orders and investment decisions i.e. that leasing can be the solution. Pointed this out several years ago, but never got a hearing. Not even a reply email. Sooo... if I had been Anders Hallberg I would treat Miris as a turnaround case where the product is proven, but the business model is not yet. After nearly 20 years on the stock exchange, around 200 MSEK (incl this additional share issue) in reported contributed equity and a turnover that is still below 20 MSEK I would not accept yet another period with only a growing order pipeline and positive customer dialogues. I would have done three things at the same time: secured liquidity, changed the sales model and recruited management that can commercialize medical technology in the USA. But... what actually surprises me the most is that Miris has had FDA approval since 2018, has hundreds of installed instruments and lacks a direct competitor with equivalent medical device approval but still hasn't managed to reach 20 MSEK in stable annual turnover... Furthermore, a new American study gives cause for concern. On September 14, 2026, JAMA Pediatrics published a randomized clinical trial where the researchers used precisely the Miris Human Milk Analyzer. The study included 130 extremely preterm infants and compared individualized nutritional fortification based on milk analysis with established standard care. The result was that the researchers could not show any significant improvement in growth, body composition or investigated measures of brain development. The researchers therefore considered that the results did not support the routine use of the investigated method. This is an important negative study to take into account
·27.10.A mess in this company, but this might be a solution to bring in new people, so that something good can happen with the new major shareholder?
I think people are just panicking a bit today.. yes the share gets diluted, but a new main shareholder who believes in the share. changes in positions might help too.. unfortunately I just think we are still hit by the later implementation of the strategy with more maintenance revenues after the sale of facilities.. remember that they have gained access to the Middle Eastern market.. now it is time to pick up cheap. I still believe in this share.- ·6.10. · MuokattuThe CEO said after the 1st quarter that it looked very good for the autumn with strong development with a growing order pipeline and great interest from clinics and researchers and coming revenue. Since then you haven't heard a peep from Miris which is a very quiet company :-(
- ·28.8."We are entering the autumn with several positive signals in the market. Although there is still work to be done to recover the weaker sales during the first quarter, it is gratifying to see several positive signals: growth during the second quarter, continued strong development of recurring revenues, a growing order pipeline, and great interest in Miris HMA from both clinicians and researchers," says Strandberg.Miris's biggest challenge may be that the company has spent almost two decades trying to commercialize a technically interesting solution for a need that has not yet become strong enough among customers. I do not understand why the previous mgt has not investigated whether milk banks are a more attractive primary market than individualized nutritional fortification in neonatal wards. There, analysis, classification, and quality assurance of milk can have a more direct operational value. It is more serious than a regular sales problem, but it is also an issue that a truly competent new management should be able to investigate relatively quickly.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
69 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·27.10. · MuokattuOj... was a shareholder in the company many years ago. I recall that when I went through all the share issues that the company had made over all the years on the stock exchange, these amounted to a total of around 200m (someone is welcome to check this). Possible if one changes the sales model around the instruments, that this could be the solution to the problem. A change from direct sales (CAPEX decision) to operational leasing (OPEX decision) definitely changes/shortens the sales process as the hospitals do not need CAPEX orders and investment decisions i.e. that leasing can be the solution. Pointed this out several years ago, but never got a hearing. Not even a reply email. Sooo... if I had been Anders Hallberg I would treat Miris as a turnaround case where the product is proven, but the business model is not yet. After nearly 20 years on the stock exchange, around 200 MSEK (incl this additional share issue) in reported contributed equity and a turnover that is still below 20 MSEK I would not accept yet another period with only a growing order pipeline and positive customer dialogues. I would have done three things at the same time: secured liquidity, changed the sales model and recruited management that can commercialize medical technology in the USA. But... what actually surprises me the most is that Miris has had FDA approval since 2018, has hundreds of installed instruments and lacks a direct competitor with equivalent medical device approval but still hasn't managed to reach 20 MSEK in stable annual turnover... Furthermore, a new American study gives cause for concern. On September 14, 2026, JAMA Pediatrics published a randomized clinical trial where the researchers used precisely the Miris Human Milk Analyzer. The study included 130 extremely preterm infants and compared individualized nutritional fortification based on milk analysis with established standard care. The result was that the researchers could not show any significant improvement in growth, body composition or investigated measures of brain development. The researchers therefore considered that the results did not support the routine use of the investigated method. This is an important negative study to take into account
- ·27.10.A mess in this company, but this might be a solution to bring in new people, so that something good can happen with the new major shareholder?I think people are just panicking a bit today.. yes the share gets diluted, but a new main shareholder who believes in the share. changes in positions might help too.. unfortunately I just think we are still hit by the later implementation of the strategy with more maintenance revenues after the sale of facilities.. remember that they have gained access to the Middle Eastern market.. now it is time to pick up cheap. I still believe in this share.
- ·6.10. · MuokattuThe CEO said after the 1st quarter that it looked very good for the autumn with strong development with a growing order pipeline and great interest from clinics and researchers and coming revenue. Since then you haven't heard a peep from Miris which is a very quiet company :-(
- ·28.8."We are entering the autumn with several positive signals in the market. Although there is still work to be done to recover the weaker sales during the first quarter, it is gratifying to see several positive signals: growth during the second quarter, continued strong development of recurring revenues, a growing order pipeline, and great interest in Miris HMA from both clinicians and researchers," says Strandberg.Miris's biggest challenge may be that the company has spent almost two decades trying to commercialize a technically interesting solution for a need that has not yet become strong enough among customers. I do not understand why the previous mgt has not investigated whether milk banks are a more attractive primary market than individualized nutritional fortification in neonatal wards. There, analysis, classification, and quality assurance of milk can have a more direct operational value. It is more serious than a regular sales problem, but it is also an issue that a truly competent new management should be able to investigate relatively quickly.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 27.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 28.8. | ||
2026 Q1 - tulosraportti 28.5. | ||
2025 Q4 - tulosraportti 11.2. | ||
2025 Q3 - tulosraportti 27.11.2025 | ||
2025 Q2 - tulosraportti 20.8.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
69 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 27.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 28.8. | ||
2026 Q1 - tulosraportti 28.5. | ||
2025 Q4 - tulosraportti 11.2. | ||
2025 Q3 - tulosraportti 27.11.2025 | ||
2025 Q2 - tulosraportti 20.8.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·27.10. · MuokattuOj... was a shareholder in the company many years ago. I recall that when I went through all the share issues that the company had made over all the years on the stock exchange, these amounted to a total of around 200m (someone is welcome to check this). Possible if one changes the sales model around the instruments, that this could be the solution to the problem. A change from direct sales (CAPEX decision) to operational leasing (OPEX decision) definitely changes/shortens the sales process as the hospitals do not need CAPEX orders and investment decisions i.e. that leasing can be the solution. Pointed this out several years ago, but never got a hearing. Not even a reply email. Sooo... if I had been Anders Hallberg I would treat Miris as a turnaround case where the product is proven, but the business model is not yet. After nearly 20 years on the stock exchange, around 200 MSEK (incl this additional share issue) in reported contributed equity and a turnover that is still below 20 MSEK I would not accept yet another period with only a growing order pipeline and positive customer dialogues. I would have done three things at the same time: secured liquidity, changed the sales model and recruited management that can commercialize medical technology in the USA. But... what actually surprises me the most is that Miris has had FDA approval since 2018, has hundreds of installed instruments and lacks a direct competitor with equivalent medical device approval but still hasn't managed to reach 20 MSEK in stable annual turnover... Furthermore, a new American study gives cause for concern. On September 14, 2026, JAMA Pediatrics published a randomized clinical trial where the researchers used precisely the Miris Human Milk Analyzer. The study included 130 extremely preterm infants and compared individualized nutritional fortification based on milk analysis with established standard care. The result was that the researchers could not show any significant improvement in growth, body composition or investigated measures of brain development. The researchers therefore considered that the results did not support the routine use of the investigated method. This is an important negative study to take into account
- ·27.10.A mess in this company, but this might be a solution to bring in new people, so that something good can happen with the new major shareholder?I think people are just panicking a bit today.. yes the share gets diluted, but a new main shareholder who believes in the share. changes in positions might help too.. unfortunately I just think we are still hit by the later implementation of the strategy with more maintenance revenues after the sale of facilities.. remember that they have gained access to the Middle Eastern market.. now it is time to pick up cheap. I still believe in this share.
- ·6.10. · MuokattuThe CEO said after the 1st quarter that it looked very good for the autumn with strong development with a growing order pipeline and great interest from clinics and researchers and coming revenue. Since then you haven't heard a peep from Miris which is a very quiet company :-(
- ·28.8."We are entering the autumn with several positive signals in the market. Although there is still work to be done to recover the weaker sales during the first quarter, it is gratifying to see several positive signals: growth during the second quarter, continued strong development of recurring revenues, a growing order pipeline, and great interest in Miris HMA from both clinicians and researchers," says Strandberg.Miris's biggest challenge may be that the company has spent almost two decades trying to commercialize a technically interesting solution for a need that has not yet become strong enough among customers. I do not understand why the previous mgt has not investigated whether milk banks are a more attractive primary market than individualized nutritional fortification in neonatal wards. There, analysis, classification, and quality assurance of milk can have a more direct operational value. It is more serious than a regular sales problem, but it is also an issue that a truly competent new management should be able to investigate relatively quickly.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Dataa ei löytynyt